VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy

Sidsel Alsing, Thomas Koed Doktor, Anne Louise Askou, Emilie Grarup Jensen, Ulvi Ahmadov, Lasse Sommer Kristensen, Brage Storstein Andresen, Lars Aagaard, Thomas J. Corydon*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

30 Downloads (Pure)


Retinal gene therapy using RNA interference (RNAi) to silence targeted genes requires both efficacy and safety. Short hairpin RNAs (shRNAs) are useful for RNAi, but high expression levels and activity from the co-delivered passenger strand may cause undesirable cellular responses. Ago2-dependent shRNAs (agshRNAs) produce no passenger strand activity. To enhance efficacy and to investigate improvements in safety, we have generated VEGFA-targeting agshRNAs and microRNA (miRNA)-embedded agshRNAs (miR-agshRNAs) and inserted these RNAi effectors in Pol II/III-driven expression cassettes and lentiviral vectors (LVs). Compared with corresponding shRNAs, agshRNAs and miR-agshRNAs increased specificity and safety, while retaining a high knockdown efficacy and abolishing passenger strand activity. The agshRNAs also caused significantly smaller reductions in cell viability and reduced competition with the processing of endogenous miR21 compared with their shRNA counterparts. RNA sequencing (RNA-seq) analysis of LV-transduced ARPE19 cells revealed that expression of shRNAs in general leads to more changes in gene expression levels compared with their agshRNA counterparts and activation of immune-related pathways. In mice, subretinal delivery of LVs encoding tissue-specific miR-agshRNAs resulted in retinal pigment epithelium (RPE)-restricted expression and significant knockdown of Vegfa in transduced RPE cells. Collectively, our data suggest that agshRNAs and miR-agshRNA possess important advantages over shRNAs, thereby posing a clinically relevant approach with respect to efficacy, specificity, and safety.

Original languageEnglish
JournalMolecular Therapy - Nucleic Acids
Pages (from-to)58-76
Number of pages19
Publication statusPublished - 14. Jun 2022


  • agoshRNA
  • agshRNA
  • Dicer-independent shRNAs
  • in vivo efficacy
  • Non-coding RNAs
  • off-target effects
  • Pol II-driven miRNA scaffold
  • retinal gene therapy
  • RNA interference
  • VEGF


Dive into the research topics of 'VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy'. Together they form a unique fingerprint.

Cite this